SubHero Banner

Descovy®(emtricitabine/tenofovir alafenamide) – Expanded indication, new strength

 On January 7, 2022, the FDA approved Gilead’s Descovy (emtricitabine/tenofovir alafenamide), in  combination with other antiretroviral agents other than protease inhibitors that require a CYP3A  inhibitor, for the treatment of HIV-1 infection in pediatric patients weighing at least 14 kg and less  than 35 kg.

Download PDF